nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—SLCO1B3—Conjugated Estrogens—osteoporosis	0.151	0.216	CbGbCtD
Valsartan—SLCO1B3—Estradiol—osteoporosis	0.133	0.19	CbGbCtD
Valsartan—ALB—Estropipate—osteoporosis	0.102	0.146	CbGbCtD
Valsartan—SLCO1B1—Conjugated Estrogens—osteoporosis	0.0879	0.126	CbGbCtD
Valsartan—SLCO1B1—Estradiol—osteoporosis	0.0772	0.11	CbGbCtD
Valsartan—CYP2C9—Estropipate—osteoporosis	0.0549	0.0785	CbGbCtD
Valsartan—ALB—Estradiol—osteoporosis	0.0423	0.0605	CbGbCtD
Valsartan—CYP2C9—Cholecalciferol—osteoporosis	0.0283	0.0404	CbGbCtD
Valsartan—CYP2C9—Estradiol—osteoporosis	0.0228	0.0326	CbGbCtD
Valsartan—Pharyngitis—Estradiol—osteoporosis	0.00029	0.00115	CcSEcCtD
Valsartan—Hypersensitivity—Estropipate—osteoporosis	0.000289	0.00115	CcSEcCtD
Valsartan—Nervous system disorder—Pamidronate—osteoporosis	0.000289	0.00115	CcSEcCtD
Valsartan—Thrombocytopenia—Pamidronate—osteoporosis	0.000288	0.00115	CcSEcCtD
Valsartan—Urinary tract disorder—Estradiol—osteoporosis	0.000288	0.00114	CcSEcCtD
Valsartan—Vomiting—Etidronic acid—osteoporosis	0.000288	0.00114	CcSEcCtD
Valsartan—Cough—Zoledronate—osteoporosis	0.000288	0.00114	CcSEcCtD
Valsartan—Connective tissue disorder—Estradiol—osteoporosis	0.000287	0.00114	CcSEcCtD
Valsartan—Urethral disorder—Estradiol—osteoporosis	0.000286	0.00114	CcSEcCtD
Valsartan—Rash—Etidronic acid—osteoporosis	0.000286	0.00113	CcSEcCtD
Valsartan—Dermatitis—Etidronic acid—osteoporosis	0.000285	0.00113	CcSEcCtD
Valsartan—Vertigo—Conjugated Estrogens—osteoporosis	0.000285	0.00113	CcSEcCtD
Valsartan—Syncope—Conjugated Estrogens—osteoporosis	0.000285	0.00113	CcSEcCtD
Valsartan—Hypersensitivity—Alendronate—osteoporosis	0.000284	0.00113	CcSEcCtD
Valsartan—Headache—Etidronic acid—osteoporosis	0.000284	0.00113	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000282	0.00112	CcSEcCtD
Valsartan—Asthenia—Estropipate—osteoporosis	0.000281	0.00112	CcSEcCtD
Valsartan—Anorexia—Pamidronate—osteoporosis	0.000281	0.00111	CcSEcCtD
Valsartan—Arthralgia—Zoledronate—osteoporosis	0.000281	0.00111	CcSEcCtD
Valsartan—Myalgia—Zoledronate—osteoporosis	0.000281	0.00111	CcSEcCtD
Valsartan—Chest pain—Zoledronate—osteoporosis	0.000281	0.00111	CcSEcCtD
Valsartan—Palpitations—Conjugated Estrogens—osteoporosis	0.00028	0.00111	CcSEcCtD
Valsartan—Insomnia—Risedronate—osteoporosis	0.00028	0.00111	CcSEcCtD
Valsartan—Anxiety—Zoledronate—osteoporosis	0.00028	0.00111	CcSEcCtD
Valsartan—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000279	0.00111	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000279	0.00111	CcSEcCtD
Valsartan—Paraesthesia—Risedronate—osteoporosis	0.000278	0.0011	CcSEcCtD
Valsartan—Pruritus—Estropipate—osteoporosis	0.000277	0.0011	CcSEcCtD
Valsartan—Asthenia—Alendronate—osteoporosis	0.000277	0.0011	CcSEcCtD
Valsartan—Hypersensitivity—Ibandronate—osteoporosis	0.000277	0.0011	CcSEcCtD
Valsartan—Cough—Conjugated Estrogens—osteoporosis	0.000277	0.0011	CcSEcCtD
Valsartan—Dyspnoea—Risedronate—osteoporosis	0.000276	0.0011	CcSEcCtD
Valsartan—Hypotension—Pamidronate—osteoporosis	0.000275	0.00109	CcSEcCtD
Valsartan—Dry mouth—Zoledronate—osteoporosis	0.000274	0.00109	CcSEcCtD
Valsartan—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000274	0.00109	CcSEcCtD
Valsartan—Fatigue—Ethinyl Estradiol—osteoporosis	0.000274	0.00109	CcSEcCtD
Valsartan—Pruritus—Alendronate—osteoporosis	0.000273	0.00108	CcSEcCtD
Valsartan—Dyspepsia—Risedronate—osteoporosis	0.000273	0.00108	CcSEcCtD
Valsartan—Constipation—Ethinyl Estradiol—osteoporosis	0.000272	0.00108	CcSEcCtD
Valsartan—Hypersensitivity—Calcitriol—osteoporosis	0.000271	0.00108	CcSEcCtD
Valsartan—Cardiac disorder—Estradiol—osteoporosis	0.000271	0.00108	CcSEcCtD
Valsartan—Arthralgia—Conjugated Estrogens—osteoporosis	0.00027	0.00107	CcSEcCtD
Valsartan—Chest pain—Conjugated Estrogens—osteoporosis	0.00027	0.00107	CcSEcCtD
Valsartan—Myalgia—Conjugated Estrogens—osteoporosis	0.00027	0.00107	CcSEcCtD
Valsartan—Asthenia—Ibandronate—osteoporosis	0.00027	0.00107	CcSEcCtD
Valsartan—Anxiety—Conjugated Estrogens—osteoporosis	0.000269	0.00107	CcSEcCtD
Valsartan—Nausea—Etidronic acid—osteoporosis	0.000269	0.00107	CcSEcCtD
Valsartan—Anaphylactic shock—Zoledronate—osteoporosis	0.000269	0.00107	CcSEcCtD
Valsartan—Oedema—Zoledronate—osteoporosis	0.000269	0.00107	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000268	0.00107	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000268	0.00107	CcSEcCtD
Valsartan—Diarrhoea—Estropipate—osteoporosis	0.000268	0.00107	CcSEcCtD
Valsartan—Gastrointestinal disorder—Risedronate—osteoporosis	0.000267	0.00106	CcSEcCtD
Valsartan—Infection—Zoledronate—osteoporosis	0.000267	0.00106	CcSEcCtD
Valsartan—Fatigue—Risedronate—osteoporosis	0.000267	0.00106	CcSEcCtD
Valsartan—Insomnia—Pamidronate—osteoporosis	0.000266	0.00106	CcSEcCtD
Valsartan—Pruritus—Ibandronate—osteoporosis	0.000266	0.00106	CcSEcCtD
Valsartan—Constipation—Risedronate—osteoporosis	0.000265	0.00105	CcSEcCtD
Valsartan—Angiopathy—Estradiol—osteoporosis	0.000265	0.00105	CcSEcCtD
Valsartan—Shock—Zoledronate—osteoporosis	0.000265	0.00105	CcSEcCtD
Valsartan—Paraesthesia—Pamidronate—osteoporosis	0.000264	0.00105	CcSEcCtD
Valsartan—Diarrhoea—Alendronate—osteoporosis	0.000264	0.00105	CcSEcCtD
Valsartan—Asthenia—Calcitriol—osteoporosis	0.000264	0.00105	CcSEcCtD
Valsartan—Nervous system disorder—Zoledronate—osteoporosis	0.000264	0.00105	CcSEcCtD
Valsartan—Immune system disorder—Estradiol—osteoporosis	0.000263	0.00105	CcSEcCtD
Valsartan—Thrombocytopenia—Zoledronate—osteoporosis	0.000263	0.00105	CcSEcCtD
Valsartan—Mediastinal disorder—Estradiol—osteoporosis	0.000263	0.00104	CcSEcCtD
Valsartan—Dyspnoea—Pamidronate—osteoporosis	0.000262	0.00104	CcSEcCtD
Valsartan—Somnolence—Pamidronate—osteoporosis	0.000262	0.00104	CcSEcCtD
Valsartan—Skin disorder—Zoledronate—osteoporosis	0.000261	0.00104	CcSEcCtD
Valsartan—Pruritus—Calcitriol—osteoporosis	0.00026	0.00103	CcSEcCtD
Valsartan—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00026	0.00103	CcSEcCtD
Valsartan—Diarrhoea—Raloxifene—osteoporosis	0.00026	0.00103	CcSEcCtD
Valsartan—Dyspepsia—Pamidronate—osteoporosis	0.000259	0.00103	CcSEcCtD
Valsartan—Dizziness—Estropipate—osteoporosis	0.000259	0.00103	CcSEcCtD
Valsartan—Oedema—Conjugated Estrogens—osteoporosis	0.000259	0.00103	CcSEcCtD
Valsartan—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000259	0.00103	CcSEcCtD
Valsartan—Alopecia—Estradiol—osteoporosis	0.000258	0.00102	CcSEcCtD
Valsartan—Infection—Conjugated Estrogens—osteoporosis	0.000257	0.00102	CcSEcCtD
Valsartan—Diarrhoea—Ibandronate—osteoporosis	0.000257	0.00102	CcSEcCtD
Valsartan—Anorexia—Zoledronate—osteoporosis	0.000256	0.00102	CcSEcCtD
Valsartan—Decreased appetite—Pamidronate—osteoporosis	0.000256	0.00102	CcSEcCtD
Valsartan—Mental disorder—Estradiol—osteoporosis	0.000256	0.00102	CcSEcCtD
Valsartan—Dizziness—Alendronate—osteoporosis	0.000255	0.00101	CcSEcCtD
Valsartan—Shock—Conjugated Estrogens—osteoporosis	0.000255	0.00101	CcSEcCtD
Valsartan—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000254	0.00101	CcSEcCtD
Valsartan—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000254	0.00101	CcSEcCtD
Valsartan—Malnutrition—Estradiol—osteoporosis	0.000254	0.00101	CcSEcCtD
Valsartan—Fatigue—Pamidronate—osteoporosis	0.000254	0.00101	CcSEcCtD
Valsartan—Gastrointestinal pain—Risedronate—osteoporosis	0.000253	0.00101	CcSEcCtD
Valsartan—Urticaria—Ethinyl Estradiol—osteoporosis	0.000252	0.001	CcSEcCtD
Valsartan—Constipation—Pamidronate—osteoporosis	0.000252	0.001	CcSEcCtD
Valsartan—Diarrhoea—Calcitriol—osteoporosis	0.000252	0.001	CcSEcCtD
Valsartan—Skin disorder—Conjugated Estrogens—osteoporosis	0.000252	0.000999	CcSEcCtD
Valsartan—Hypotension—Zoledronate—osteoporosis	0.000251	0.000998	CcSEcCtD
Valsartan—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000251	0.000998	CcSEcCtD
Valsartan—Dizziness—Raloxifene—osteoporosis	0.000251	0.000997	CcSEcCtD
Valsartan—Flatulence—Estradiol—osteoporosis	0.00025	0.000994	CcSEcCtD
Valsartan—Vomiting—Estropipate—osteoporosis	0.000249	0.00099	CcSEcCtD
Valsartan—Dysgeusia—Estradiol—osteoporosis	0.000249	0.000988	CcSEcCtD
Valsartan—Dizziness—Ibandronate—osteoporosis	0.000249	0.000987	CcSEcCtD
Valsartan—Rash—Estropipate—osteoporosis	0.000247	0.000982	CcSEcCtD
Valsartan—Dermatitis—Estropipate—osteoporosis	0.000247	0.000981	CcSEcCtD
Valsartan—Anorexia—Conjugated Estrogens—osteoporosis	0.000247	0.000981	CcSEcCtD
Valsartan—Urticaria—Risedronate—osteoporosis	0.000246	0.000977	CcSEcCtD
Valsartan—Back pain—Estradiol—osteoporosis	0.000246	0.000976	CcSEcCtD
Valsartan—Headache—Estropipate—osteoporosis	0.000246	0.000975	CcSEcCtD
Valsartan—Vomiting—Alendronate—osteoporosis	0.000245	0.000975	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000245	0.000973	CcSEcCtD
Valsartan—Abdominal pain—Risedronate—osteoporosis	0.000245	0.000973	CcSEcCtD
Valsartan—Muscle spasms—Estradiol—osteoporosis	0.000244	0.00097	CcSEcCtD
Valsartan—Rash—Alendronate—osteoporosis	0.000243	0.000967	CcSEcCtD
Valsartan—Insomnia—Zoledronate—osteoporosis	0.000243	0.000966	CcSEcCtD
Valsartan—Dermatitis—Alendronate—osteoporosis	0.000243	0.000966	CcSEcCtD
Valsartan—Hypotension—Conjugated Estrogens—osteoporosis	0.000242	0.000961	CcSEcCtD
Valsartan—Headache—Alendronate—osteoporosis	0.000242	0.000961	CcSEcCtD
Valsartan—Paraesthesia—Zoledronate—osteoporosis	0.000241	0.000959	CcSEcCtD
Valsartan—Vomiting—Raloxifene—osteoporosis	0.000241	0.000959	CcSEcCtD
Valsartan—Gastrointestinal pain—Pamidronate—osteoporosis	0.000241	0.000956	CcSEcCtD
Valsartan—Dyspnoea—Zoledronate—osteoporosis	0.00024	0.000953	CcSEcCtD
Valsartan—Rash—Raloxifene—osteoporosis	0.000239	0.000951	CcSEcCtD
Valsartan—Dermatitis—Raloxifene—osteoporosis	0.000239	0.00095	CcSEcCtD
Valsartan—Somnolence—Zoledronate—osteoporosis	0.000239	0.00095	CcSEcCtD
Valsartan—Vomiting—Ibandronate—osteoporosis	0.000239	0.000949	CcSEcCtD
Valsartan—Headache—Raloxifene—osteoporosis	0.000238	0.000945	CcSEcCtD
Valsartan—Rash—Ibandronate—osteoporosis	0.000237	0.000941	CcSEcCtD
Valsartan—Dermatitis—Ibandronate—osteoporosis	0.000237	0.000941	CcSEcCtD
Valsartan—Dyspepsia—Zoledronate—osteoporosis	0.000237	0.00094	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000236	0.000937	CcSEcCtD
Valsartan—Headache—Ibandronate—osteoporosis	0.000235	0.000935	CcSEcCtD
Valsartan—Insomnia—Conjugated Estrogens—osteoporosis	0.000234	0.00093	CcSEcCtD
Valsartan—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000234	0.00093	CcSEcCtD
Valsartan—Vomiting—Calcitriol—osteoporosis	0.000234	0.000929	CcSEcCtD
Valsartan—Decreased appetite—Zoledronate—osteoporosis	0.000234	0.000929	CcSEcCtD
Valsartan—Nausea—Estropipate—osteoporosis	0.000233	0.000925	CcSEcCtD
Valsartan—Abdominal pain—Pamidronate—osteoporosis	0.000233	0.000925	CcSEcCtD
Valsartan—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000233	0.000924	CcSEcCtD
Valsartan—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000232	0.000922	CcSEcCtD
Valsartan—Angioedema—Estradiol—osteoporosis	0.000232	0.000922	CcSEcCtD
Valsartan—Rash—Calcitriol—osteoporosis	0.000232	0.000922	CcSEcCtD
Valsartan—Fatigue—Zoledronate—osteoporosis	0.000232	0.000921	CcSEcCtD
Valsartan—Dermatitis—Calcitriol—osteoporosis	0.000232	0.000921	CcSEcCtD
Valsartan—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000231	0.000917	CcSEcCtD
Valsartan—Headache—Calcitriol—osteoporosis	0.00023	0.000916	CcSEcCtD
Valsartan—Somnolence—Conjugated Estrogens—osteoporosis	0.00023	0.000915	CcSEcCtD
Valsartan—Constipation—Zoledronate—osteoporosis	0.00023	0.000914	CcSEcCtD
Valsartan—Nausea—Alendronate—osteoporosis	0.000229	0.000911	CcSEcCtD
Valsartan—Hypersensitivity—Risedronate—osteoporosis	0.000228	0.000907	CcSEcCtD
Valsartan—Vertigo—Estradiol—osteoporosis	0.000228	0.000906	CcSEcCtD
Valsartan—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000228	0.000906	CcSEcCtD
Valsartan—Asthenia—Ethinyl Estradiol—osteoporosis	0.000228	0.000905	CcSEcCtD
Valsartan—Syncope—Estradiol—osteoporosis	0.000228	0.000905	CcSEcCtD
Valsartan—Nausea—Raloxifene—osteoporosis	0.000225	0.000896	CcSEcCtD
Valsartan—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000225	0.000894	CcSEcCtD
Valsartan—Pruritus—Ethinyl Estradiol—osteoporosis	0.000225	0.000893	CcSEcCtD
Valsartan—Palpitations—Estradiol—osteoporosis	0.000224	0.000892	CcSEcCtD
Valsartan—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000224	0.000888	CcSEcCtD
Valsartan—Fatigue—Conjugated Estrogens—osteoporosis	0.000223	0.000887	CcSEcCtD
Valsartan—Nausea—Ibandronate—osteoporosis	0.000223	0.000887	CcSEcCtD
Valsartan—Loss of consciousness—Estradiol—osteoporosis	0.000223	0.000887	CcSEcCtD
Valsartan—Asthenia—Risedronate—osteoporosis	0.000222	0.000883	CcSEcCtD
Valsartan—Cough—Estradiol—osteoporosis	0.000222	0.00088	CcSEcCtD
Valsartan—Constipation—Conjugated Estrogens—osteoporosis	0.000221	0.00088	CcSEcCtD
Valsartan—Gastrointestinal pain—Zoledronate—osteoporosis	0.00022	0.000874	CcSEcCtD
Valsartan—Pruritus—Risedronate—osteoporosis	0.000219	0.000871	CcSEcCtD
Valsartan—Nausea—Calcitriol—osteoporosis	0.000219	0.000868	CcSEcCtD
Valsartan—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000217	0.000863	CcSEcCtD
Valsartan—Hypersensitivity—Pamidronate—osteoporosis	0.000217	0.000862	CcSEcCtD
Valsartan—Myalgia—Estradiol—osteoporosis	0.000216	0.000859	CcSEcCtD
Valsartan—Arthralgia—Estradiol—osteoporosis	0.000216	0.000859	CcSEcCtD
Valsartan—Chest pain—Estradiol—osteoporosis	0.000216	0.000859	CcSEcCtD
Valsartan—Anxiety—Estradiol—osteoporosis	0.000215	0.000856	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000215	0.000853	CcSEcCtD
Valsartan—Losartan—ACE—osteoporosis	0.000214	1	CrCbGaD
Valsartan—Urticaria—Zoledronate—osteoporosis	0.000214	0.000849	CcSEcCtD
Valsartan—Abdominal pain—Zoledronate—osteoporosis	0.000213	0.000845	CcSEcCtD
Valsartan—Diarrhoea—Risedronate—osteoporosis	0.000212	0.000842	CcSEcCtD
Valsartan—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000212	0.000841	CcSEcCtD
Valsartan—Dry mouth—Estradiol—osteoporosis	0.000211	0.00084	CcSEcCtD
Valsartan—Asthenia—Pamidronate—osteoporosis	0.000211	0.000839	CcSEcCtD
Valsartan—Dizziness—Ethinyl Estradiol—osteoporosis	0.00021	0.000835	CcSEcCtD
Valsartan—Pruritus—Pamidronate—osteoporosis	0.000208	0.000828	CcSEcCtD
Valsartan—Anaphylactic shock—Estradiol—osteoporosis	0.000207	0.000823	CcSEcCtD
Valsartan—Oedema—Estradiol—osteoporosis	0.000207	0.000823	CcSEcCtD
Valsartan—Infection—Estradiol—osteoporosis	0.000206	0.000818	CcSEcCtD
Valsartan—Urticaria—Conjugated Estrogens—osteoporosis	0.000206	0.000817	CcSEcCtD
Valsartan—Dizziness—Risedronate—osteoporosis	0.000205	0.000814	CcSEcCtD
Valsartan—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000205	0.000813	CcSEcCtD
Valsartan—Shock—Estradiol—osteoporosis	0.000204	0.00081	CcSEcCtD
Valsartan—Nervous system disorder—Estradiol—osteoporosis	0.000203	0.000807	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—PTH—osteoporosis	0.000203	0.00412	CbGpPWpGaD
Valsartan—Vomiting—Ethinyl Estradiol—osteoporosis	0.000202	0.000802	CcSEcCtD
Valsartan—Diarrhoea—Pamidronate—osteoporosis	0.000201	0.0008	CcSEcCtD
Valsartan—Skin disorder—Estradiol—osteoporosis	0.000201	0.0008	CcSEcCtD
Valsartan—Rash—Ethinyl Estradiol—osteoporosis	0.0002	0.000796	CcSEcCtD
Valsartan—Dermatitis—Ethinyl Estradiol—osteoporosis	0.0002	0.000795	CcSEcCtD
Valsartan—Headache—Ethinyl Estradiol—osteoporosis	0.000199	0.000791	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—CALCR—osteoporosis	0.000198	0.00402	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PTH1R—osteoporosis	0.000198	0.00402	CbGpPWpGaD
Valsartan—Hypersensitivity—Zoledronate—osteoporosis	0.000198	0.000787	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CNR2—osteoporosis	0.000198	0.00401	CbGpPWpGaD
Valsartan—Vomiting—Risedronate—osteoporosis	0.000197	0.000782	CcSEcCtD
Valsartan—Rash—Risedronate—osteoporosis	0.000195	0.000776	CcSEcCtD
Valsartan—Dermatitis—Risedronate—osteoporosis	0.000195	0.000775	CcSEcCtD
Valsartan—Dizziness—Pamidronate—osteoporosis	0.000195	0.000773	CcSEcCtD
Valsartan—Headache—Risedronate—osteoporosis	0.000194	0.000771	CcSEcCtD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000193	0.00392	CbGpPWpGaD
Valsartan—Asthenia—Zoledronate—osteoporosis	0.000193	0.000767	CcSEcCtD
Valsartan—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000191	0.000758	CcSEcCtD
Valsartan—Pruritus—Zoledronate—osteoporosis	0.00019	0.000756	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.00019	0.00385	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000189	0.00075	CcSEcCtD
Valsartan—Nausea—Ethinyl Estradiol—osteoporosis	0.000189	0.00075	CcSEcCtD
Valsartan—Insomnia—Estradiol—osteoporosis	0.000187	0.000745	CcSEcCtD
Valsartan—Vomiting—Pamidronate—osteoporosis	0.000187	0.000744	CcSEcCtD
Valsartan—Paraesthesia—Estradiol—osteoporosis	0.000186	0.000739	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—WNT1—osteoporosis	0.000186	0.00377	CbGpPWpGaD
Valsartan—Asthenia—Conjugated Estrogens—osteoporosis	0.000186	0.000738	CcSEcCtD
Valsartan—Rash—Pamidronate—osteoporosis	0.000186	0.000738	CcSEcCtD
Valsartan—Dermatitis—Pamidronate—osteoporosis	0.000185	0.000737	CcSEcCtD
Valsartan—Dyspnoea—Estradiol—osteoporosis	0.000185	0.000734	CcSEcCtD
Valsartan—Headache—Pamidronate—osteoporosis	0.000184	0.000733	CcSEcCtD
Valsartan—Somnolence—Estradiol—osteoporosis	0.000184	0.000732	CcSEcCtD
Valsartan—Diarrhoea—Zoledronate—osteoporosis	0.000184	0.000731	CcSEcCtD
Valsartan—Nausea—Risedronate—osteoporosis	0.000184	0.000731	CcSEcCtD
Valsartan—Pruritus—Conjugated Estrogens—osteoporosis	0.000183	0.000728	CcSEcCtD
Valsartan—Dyspepsia—Estradiol—osteoporosis	0.000182	0.000725	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—MTHFR—osteoporosis	0.000182	0.00369	CbGpPWpGaD
Valsartan—Decreased appetite—Estradiol—osteoporosis	0.00018	0.000716	CcSEcCtD
Valsartan—Gastrointestinal disorder—Estradiol—osteoporosis	0.000179	0.000711	CcSEcCtD
Valsartan—Fatigue—Estradiol—osteoporosis	0.000179	0.00071	CcSEcCtD
Valsartan—ALB—Platelet activation, signaling and aggregation—MGLL—osteoporosis	0.000178	0.00362	CbGpPWpGaD
Valsartan—Dizziness—Zoledronate—osteoporosis	0.000178	0.000707	CcSEcCtD
Valsartan—Constipation—Estradiol—osteoporosis	0.000177	0.000704	CcSEcCtD
Valsartan—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000177	0.000704	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TGFB1—osteoporosis	0.000176	0.00358	CbGpPWpGaD
Valsartan—Nausea—Pamidronate—osteoporosis	0.000175	0.000695	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000174	0.00354	CbGpPWpGaD
Valsartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000174	0.00353	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—MGLL—osteoporosis	0.000173	0.00352	CbGpPWpGaD
Valsartan—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000172	0.00348	CbGpPWpGaD
Valsartan—Dizziness—Conjugated Estrogens—osteoporosis	0.000171	0.00068	CcSEcCtD
Valsartan—Vomiting—Zoledronate—osteoporosis	0.000171	0.000679	CcSEcCtD
Valsartan—Rash—Zoledronate—osteoporosis	0.00017	0.000674	CcSEcCtD
Valsartan—Gastrointestinal pain—Estradiol—osteoporosis	0.000169	0.000673	CcSEcCtD
Valsartan—Dermatitis—Zoledronate—osteoporosis	0.000169	0.000673	CcSEcCtD
Valsartan—Headache—Zoledronate—osteoporosis	0.000168	0.000669	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—PTHLH—osteoporosis	0.000168	0.00341	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—SOD2—osteoporosis	0.000168	0.00341	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—TNF—osteoporosis	0.000165	0.00334	CbGpPWpGaD
Valsartan—Vomiting—Conjugated Estrogens—osteoporosis	0.000165	0.000654	CcSEcCtD
Valsartan—Urticaria—Estradiol—osteoporosis	0.000165	0.000654	CcSEcCtD
Valsartan—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	0.000164	0.00333	CbGpPWpGaD
Valsartan—Abdominal pain—Estradiol—osteoporosis	0.000164	0.000651	CcSEcCtD
Valsartan—Rash—Conjugated Estrogens—osteoporosis	0.000163	0.000649	CcSEcCtD
Valsartan—Dermatitis—Conjugated Estrogens—osteoporosis	0.000163	0.000648	CcSEcCtD
Valsartan—ALB—Platelet activation, signaling and aggregation—PLEK—osteoporosis	0.000163	0.00331	CbGpPWpGaD
Valsartan—Headache—Conjugated Estrogens—osteoporosis	0.000162	0.000644	CcSEcCtD
Valsartan—ALB—Folate Metabolism—GPX1—osteoporosis	0.00016	0.00325	CbGpPWpGaD
Valsartan—Nausea—Zoledronate—osteoporosis	0.00016	0.000635	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—MGLL—osteoporosis	0.000157	0.0032	CbGpPWpGaD
Valsartan—Nausea—Conjugated Estrogens—osteoporosis	0.000154	0.000611	CcSEcCtD
Valsartan—Hypersensitivity—Estradiol—osteoporosis	0.000153	0.000607	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—POMC—osteoporosis	0.000152	0.00308	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.00015	0.00305	CbGpPWpGaD
Valsartan—Asthenia—Estradiol—osteoporosis	0.000149	0.000591	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000148	0.00301	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CALCA—osteoporosis	0.000148	0.003	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—MTHFR—osteoporosis	0.000148	0.003	CbGpPWpGaD
Valsartan—Pruritus—Estradiol—osteoporosis	0.000147	0.000583	CcSEcCtD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000146	0.00297	CbGpPWpGaD
Valsartan—ALB—Hemostasis—WDR1—osteoporosis	0.000146	0.00297	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	0.000143	0.00289	CbGpPWpGaD
Valsartan—Diarrhoea—Estradiol—osteoporosis	0.000142	0.000563	CcSEcCtD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000141	0.00286	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	0.000141	0.00285	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TLN1—osteoporosis	0.000141	0.00285	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VCL—osteoporosis	0.000139	0.00281	CbGpPWpGaD
Valsartan—Dizziness—Estradiol—osteoporosis	0.000137	0.000544	CcSEcCtD
Valsartan—SLCO1B3—Metabolism—FDPS—osteoporosis	0.000135	0.00274	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PKM—osteoporosis	0.000135	0.00274	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000134	0.00272	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—SOD2—osteoporosis	0.000134	0.00271	CbGpPWpGaD
Valsartan—Vomiting—Estradiol—osteoporosis	0.000132	0.000524	CcSEcCtD
Valsartan—Rash—Estradiol—osteoporosis	0.000131	0.000519	CcSEcCtD
Valsartan—Dermatitis—Estradiol—osteoporosis	0.000131	0.000519	CcSEcCtD
Valsartan—Headache—Estradiol—osteoporosis	0.00013	0.000516	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—SOST—osteoporosis	0.000129	0.00263	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GPD2—osteoporosis	0.000128	0.0026	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PGLS—osteoporosis	0.000128	0.0026	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—GPX1—osteoporosis	0.000127	0.00258	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000127	0.00258	CbGpPWpGaD
Valsartan—Nausea—Estradiol—osteoporosis	0.000123	0.000489	CcSEcCtD
Valsartan—ALB—Selenium Micronutrient Network—MTHFR—osteoporosis	0.000118	0.00239	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ATIC—osteoporosis	0.000117	0.00238	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PNP—osteoporosis	0.000117	0.00238	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTH1R—osteoporosis	0.000117	0.00238	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CALCR—osteoporosis	0.000117	0.00238	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000117	0.00238	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000116	0.00236	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—RAP1A—osteoporosis	0.000116	0.00235	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CAP1—osteoporosis	0.000116	0.00235	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PTH—osteoporosis	0.000115	0.00233	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CNR2—osteoporosis	0.000112	0.00227	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.00011	0.00224	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL1B—osteoporosis	0.000108	0.00219	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—FGA—osteoporosis	0.000105	0.00213	CbGpPWpGaD
Valsartan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000105	0.00212	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PTH—osteoporosis	0.000104	0.00211	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000102	0.00206	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CNR2—osteoporosis	0.000101	0.00206	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CA2—osteoporosis	9.96e-05	0.00202	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—OXCT1—osteoporosis	9.96e-05	0.00202	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	9.95e-05	0.00202	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—IGF1—osteoporosis	9.76e-05	0.00198	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MGLL—osteoporosis	9.71e-05	0.00197	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—FGB—osteoporosis	9.56e-05	0.00194	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—WNT1—osteoporosis	9.54e-05	0.00194	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	9.53e-05	0.00193	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PTHLH—osteoporosis	9.5e-05	0.00193	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MGLL—osteoporosis	9.3e-05	0.00189	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—osteoporosis	9.3e-05	0.00189	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MGLL—osteoporosis	9.19e-05	0.00187	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	9.15e-05	0.00186	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LRP5—osteoporosis	9.08e-05	0.00184	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PKM—osteoporosis	9.08e-05	0.00184	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—FDPS—osteoporosis	9.08e-05	0.00184	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	9.04e-05	0.00183	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL1B—osteoporosis	8.78e-05	0.00178	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LRP6—osteoporosis	8.68e-05	0.00176	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PTHLH—osteoporosis	8.63e-05	0.00175	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PGLS—osteoporosis	8.61e-05	0.00175	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPD2—osteoporosis	8.61e-05	0.00175	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	8.59e-05	0.00174	CbGpPWpGaD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	8.47e-05	0.00172	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ANXA2—osteoporosis	8.41e-05	0.00171	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLEK—osteoporosis	8.41e-05	0.00171	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	8.37e-05	0.0017	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CALCA—osteoporosis	8.36e-05	0.0017	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—IDH2—osteoporosis	8.25e-05	0.00168	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PNP—osteoporosis	7.87e-05	0.0016	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ATIC—osteoporosis	7.87e-05	0.0016	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—osteoporosis	7.83e-05	0.00159	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP27A1—osteoporosis	7.76e-05	0.00157	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—POMC—osteoporosis	7.74e-05	0.00157	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CALCA—osteoporosis	7.6e-05	0.00154	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ACP5—osteoporosis	7.55e-05	0.00153	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	7.49e-05	0.00152	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.45e-05	0.00151	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	7.39e-05	0.0015	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TLN1—osteoporosis	7.33e-05	0.00149	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ANXA2—osteoporosis	7.28e-05	0.00148	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TLN1—osteoporosis	7.24e-05	0.00147	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VCL—osteoporosis	7.15e-05	0.00145	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ADCY5—osteoporosis	7.11e-05	0.00144	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	7.03e-05	0.00143	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TPI1—osteoporosis	7.02e-05	0.00142	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL1B—osteoporosis	6.98e-05	0.00142	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	6.85e-05	0.00139	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CA2—osteoporosis	6.69e-05	0.00136	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—OXCT1—osteoporosis	6.69e-05	0.00136	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	6.69e-05	0.00136	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—P4HB—osteoporosis	6.6e-05	0.00134	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MGLL—osteoporosis	6.52e-05	0.00132	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GAPDH—osteoporosis	6.48e-05	0.00131	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—osteoporosis	6.37e-05	0.00129	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—P4HB—osteoporosis	6.32e-05	0.00128	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL6—osteoporosis	6.32e-05	0.00128	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—RAP1A—osteoporosis	6.31e-05	0.00128	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTH—osteoporosis	6.15e-05	0.00125	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	6.15e-05	0.00125	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RAP1A—osteoporosis	6.04e-05	0.00123	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CNR2—osteoporosis	5.99e-05	0.00122	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RAP1A—osteoporosis	5.97e-05	0.00121	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	5.97e-05	0.00121	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—ADCY5—osteoporosis	5.95e-05	0.00121	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFATC1—osteoporosis	5.9e-05	0.0012	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—DKK1—osteoporosis	5.85e-05	0.00119	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—TGFB1—osteoporosis	5.85e-05	0.00119	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	5.69e-05	0.00115	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—WNT1—osteoporosis	5.64e-05	0.00114	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—osteoporosis	5.57e-05	0.00113	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—IDH2—osteoporosis	5.55e-05	0.00113	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.5e-05	0.00112	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGA—osteoporosis	5.48e-05	0.00111	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	5.47e-05	0.00111	CbGpPWpGaD
Valsartan—ALB—Hemostasis—FGA—osteoporosis	5.42e-05	0.0011	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—ADCY5—osteoporosis	5.4e-05	0.0011	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP27A1—osteoporosis	5.21e-05	0.00106	CbGpPWpGaD
Valsartan—ALB—Metabolism—FDPS—osteoporosis	5.19e-05	0.00105	CbGpPWpGaD
Valsartan—ALB—Metabolism—PKM—osteoporosis	5.19e-05	0.00105	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—osteoporosis	5.14e-05	0.00104	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ENO1—osteoporosis	5.1e-05	0.00103	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTHLH—osteoporosis	5.1e-05	0.00103	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BMP2—osteoporosis	5.1e-05	0.00103	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ACP5—osteoporosis	5.07e-05	0.00103	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—osteoporosis	5.06e-05	0.00103	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PSMA2—osteoporosis	5.02e-05	0.00102	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PSMA5—osteoporosis	5.02e-05	0.00102	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.01e-05	0.00102	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGB—osteoporosis	4.99e-05	0.00101	CbGpPWpGaD
Valsartan—ALB—Hemostasis—FGB—osteoporosis	4.93e-05	0.001	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPD2—osteoporosis	4.92e-05	0.000998	CbGpPWpGaD
Valsartan—ALB—Metabolism—PGLS—osteoporosis	4.92e-05	0.000998	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PSMA2—osteoporosis	4.81e-05	0.000977	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PSMA5—osteoporosis	4.81e-05	0.000977	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ADCY5—osteoporosis	4.78e-05	0.00097	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TPI1—osteoporosis	4.72e-05	0.000957	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	4.66e-05	0.000945	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—POMC—osteoporosis	4.5e-05	0.000914	CbGpPWpGaD
Valsartan—ALB—Metabolism—PNP—osteoporosis	4.5e-05	0.000913	CbGpPWpGaD
Valsartan—ALB—Metabolism—ATIC—osteoporosis	4.5e-05	0.000913	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CALCA—osteoporosis	4.49e-05	0.000911	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—P4HB—osteoporosis	4.43e-05	0.0009	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—POMC—osteoporosis	4.38e-05	0.000888	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GAPDH—osteoporosis	4.35e-05	0.000883	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IGF1—osteoporosis	4.33e-05	0.000878	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PKM—osteoporosis	4.25e-05	0.000862	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—FDPS—osteoporosis	4.25e-05	0.000862	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—RAP1A—osteoporosis	4.24e-05	0.00086	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—osteoporosis	4.08e-05	0.000829	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP19A1—osteoporosis	4.08e-05	0.000827	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KL—osteoporosis	4.07e-05	0.000827	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PGLS—osteoporosis	4.02e-05	0.000817	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPD2—osteoporosis	4.02e-05	0.000817	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—POMC—osteoporosis	3.97e-05	0.000807	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6R—osteoporosis	3.88e-05	0.000787	CbGpPWpGaD
Valsartan—ALB—Metabolism—OXCT1—osteoporosis	3.82e-05	0.000776	CbGpPWpGaD
Valsartan—ALB—Metabolism—CA2—osteoporosis	3.82e-05	0.000776	CbGpPWpGaD
Valsartan—ALB—Metabolism—MGLL—osteoporosis	3.73e-05	0.000756	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.7e-05	0.00075	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PNP—osteoporosis	3.68e-05	0.000747	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ATIC—osteoporosis	3.68e-05	0.000747	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.51e-05	0.000713	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ENO1—osteoporosis	3.43e-05	0.000695	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PSMA5—osteoporosis	3.38e-05	0.000685	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PSMA2—osteoporosis	3.38e-05	0.000685	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ADCY5—osteoporosis	3.33e-05	0.000676	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GPX1—osteoporosis	3.32e-05	0.000674	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ADCY5—osteoporosis	3.19e-05	0.000648	CbGpPWpGaD
Valsartan—ALB—Metabolism—IDH2—osteoporosis	3.17e-05	0.000643	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CA2—osteoporosis	3.13e-05	0.000635	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—OXCT1—osteoporosis	3.13e-05	0.000635	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SPP1—osteoporosis	3.09e-05	0.000627	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MTHFR—osteoporosis	3.06e-05	0.000622	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MGLL—osteoporosis	3.05e-05	0.000619	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP27A1—osteoporosis	2.98e-05	0.000605	CbGpPWpGaD
Valsartan—ALB—Metabolism—ACP5—osteoporosis	2.9e-05	0.000588	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.88e-05	0.000584	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.86e-05	0.000581	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IRS2—osteoporosis	2.79e-05	0.000567	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP19A1—osteoporosis	2.74e-05	0.000556	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LEP—osteoporosis	2.73e-05	0.000555	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.73e-05	0.000554	CbGpPWpGaD
Valsartan—ALB—Metabolism—TPI1—osteoporosis	2.69e-05	0.000547	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ESR1—osteoporosis	2.61e-05	0.00053	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	2.59e-05	0.000527	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—IDH2—osteoporosis	2.59e-05	0.000526	CbGpPWpGaD
Valsartan—ALB—Metabolism—P4HB—osteoporosis	2.53e-05	0.000514	CbGpPWpGaD
Valsartan—ALB—Metabolism—GAPDH—osteoporosis	2.49e-05	0.000505	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—POMC—osteoporosis	2.45e-05	0.000497	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP27A1—osteoporosis	2.44e-05	0.000495	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IRS1—osteoporosis	2.44e-05	0.000495	CbGpPWpGaD
Valsartan—ALB—Metabolism—RAP1A—osteoporosis	2.42e-05	0.000491	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ACP5—osteoporosis	2.37e-05	0.000481	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—POMC—osteoporosis	2.35e-05	0.000476	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.34e-05	0.000475	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6R—osteoporosis	2.29e-05	0.000465	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—osteoporosis	2.26e-05	0.000458	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ADCY5—osteoporosis	2.24e-05	0.000454	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—osteoporosis	2.23e-05	0.000453	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPX1—osteoporosis	2.23e-05	0.000453	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TPI1—osteoporosis	2.21e-05	0.000448	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.11e-05	0.000429	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—P4HB—osteoporosis	2.07e-05	0.000421	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—osteoporosis	2.06e-05	0.000418	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GAPDH—osteoporosis	2.03e-05	0.000413	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—RAP1A—osteoporosis	1.98e-05	0.000402	CbGpPWpGaD
Valsartan—ALB—Metabolism—ENO1—osteoporosis	1.96e-05	0.000397	CbGpPWpGaD
Valsartan—ALB—Metabolism—PSMA5—osteoporosis	1.93e-05	0.000391	CbGpPWpGaD
Valsartan—ALB—Metabolism—PSMA2—osteoporosis	1.93e-05	0.000391	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.73e-05	0.000351	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—osteoporosis	1.73e-05	0.00035	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—POMC—osteoporosis	1.65e-05	0.000334	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ENO1—osteoporosis	1.6e-05	0.000325	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PSMA2—osteoporosis	1.58e-05	0.00032	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PSMA5—osteoporosis	1.58e-05	0.00032	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP19A1—osteoporosis	1.56e-05	0.000318	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—osteoporosis	1.36e-05	0.000275	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—osteoporosis	1.35e-05	0.000275	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—osteoporosis	1.34e-05	0.000271	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.28e-05	0.00026	CbGpPWpGaD
Valsartan—ALB—Metabolism—ADCY5—osteoporosis	1.28e-05	0.000259	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX1—osteoporosis	1.27e-05	0.000259	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—osteoporosis	1.18e-05	0.000239	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADCY5—osteoporosis	1.05e-05	0.000212	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX1—osteoporosis	1.04e-05	0.000212	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—osteoporosis	1.02e-05	0.000207	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—osteoporosis	9.62e-06	0.000195	CbGpPWpGaD
Valsartan—ALB—Metabolism—POMC—osteoporosis	9.4e-06	0.000191	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—POMC—osteoporosis	7.7e-06	0.000156	CbGpPWpGaD
